RARE Shares Outstanding History



Below is a table of the RARE shares outstanding history going back to 1/31/2014:

Date RARE Shares Outstanding
1/31/201428.14M
3/14/201430.04M
5/7/201430.04M
8/6/201431.70M
11/3/201431.90M
3/23/201535.60M
5/6/201535.90M
8/7/201538.68M
11/4/201538.83M
2/19/201638.98M
5/4/201639.02M
8/3/201639.44M
11/3/201640.86M
2/13/201741.73M
5/1/201742.31M
7/24/201742.46M
10/30/201742.59M
2/15/201849.61M
5/3/201849.77M
7/30/201850.18M
10/30/201850.58M
2/14/201951.28M
5/1/201957.47M
7/26/201957.69M
8/28/201920.85M
10/31/201957.77M
2/10/202057.89M
5/1/202059.75M
7/27/202060.59M
10/22/202061.04M
2/8/202166.95M
4/30/202167.48M
7/28/202167.84M
10/28/202168.16M
2/10/202269.38M
5/2/202269.93M
7/25/202270.04M
10/28/202270.11M
2/13/202370.22M
5/1/202370.81M
7/31/202371.49M
10/30/202382.11M
2/15/202482.34M
4/26/202483.13M

Also see: RARE Market Cap History
RARE YTD Return
RARE Historical Shares Outstanding:
+11.16% CAGR
RARE Historical Shares Outstanding: +11.16% CAGR

Mouse over chart for data details
1/31/2014 ...4/26/2024
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia. We show 44 historical shares outstanding datapoints in our coverage of RARE's shares outstanding history.

Understanding the changing numbers of RARE shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like RARE versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching RARE by allowing them to research RARE shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree RARE Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Ultragenyx Pharmaceutical (RARE) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

RARX Shares Outstanding History
RBOT Shares Outstanding History
RCEL Shares Outstanding History
RCKT Shares Outstanding History
RCUS Shares Outstanding History
RDHL Shares Outstanding History
RDNT Shares Outstanding History
RDY Shares Outstanding History
REGN Shares Outstanding History
RENB Shares Outstanding History
More Healthcare companies »

 

RARE Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.